Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Pharmaceuticals & Biotech
Create a narrative
Swedish Orphan Biovitrum Community
OM:SOBI Community
1
Narratives
written by author
0
Comments
on narratives written by author
14
Fair Values set
on narratives written by author
Create a narrative
Swedish Orphan Biovitrum
Popular
Undervalued
Overvalued
Community Investing Ideas
Swedish Orphan Biovitrum
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
Altuvoct Adoption And Gamifant Launches Will Unlock European Opportunities
Key Takeaways Successful Altuvoct launch in Europe and expanding regulatory approvals for Aspaveli and Gamifant could significantly boost revenue through market share growth and new entries. Strategic operational efficiency, cost management, and increased Beyfortus royalties are expected to enhance margins and stabilize earnings.
View narrative
SEK 344.50
FV
18.0% undervalued
intrinsic discount
10.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
about 21 hours ago
author updated this narrative
Your Valuation for
SOBI
SOBI
Swedish Orphan Biovitrum
Your Fair Value
SEK
Current Price
SEK 282.40
15.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
42b
2015
2018
2021
2024
2025
2027
2030
Revenue SEK 42.1b
Earnings SEK 6.8b
Advanced
Set Fair Value